Secukinumab may be a safe and effective treatment for patients with psoriatic disease, comorbidities, and treatment failure, according to results of a retrospective study published in Dermatologic Therapy. The fully human IgG1\/k monoclonal antibody has been shown to be safe and effective in the treatment of psoriasis in phase 3 trials, but has not yet been tested in the general population.<\/p>\n
To determine the clinical effectiveness and safety of secukinumab in a real-life cohort of patients with moderate to severe psoriasis vulgaris, data from 120 patients (35.8% women) were analyzed. The mean age of participants was 49.813.5 years and 65% of participants were diagnosed with additional forms of psoriasis. The extent and severity of psoriasis was measured using the Psoriasis Area Severity Index (PASI).<\/p>\n
After 3 months of secukinumab therapy, the mean PASI of the entire population was significantly lower than baseline (P <.001) and was maintained at 12 month follow-up (P <.001). Total clearance (PASI 0) was achieved after 12 months in 46% of those with psoriatic onychopathy (1 of the more difficult forms of psoriasis to treat), 75% of patients with moderate to severe scalp psoriasis, 57% of patients with psoriasis of the genital area, and 38% of patients with palmoplantar psoriasis. In all, 28 adverse effects were recorded in the first year of treatment, resulting in 8 patients discontinuing treatment. After 12 months, patients who had been unresponsive to 2 or more lines of biologic agents had a lower rate of treatment persistence (71%) than those who were bio-naive (93%) or had a history of inefficacy to only 1 biologic agent (88%)(P =.009 for trend).<\/p>\n
Limitations to this study include its small cohort and retrospective design. Future research with a larger cohort and that investigates the impact of body mass index on therapeutic effectiveness are warranted.<\/p>\n
The results of this study indicated to the researchers that secukinumab is effective and safe in the treatment of psoriasis in patients with a range of comorbidities and in areas that are difficult to treat. These results were significant despite a mean persistence to treatment of 85% after 12 months.<\/p>\n
Disclosure: Medical writing assistance for this publication was provided by Novartis. Please see the original reference for a full list of authors disclosures.<\/p>\n
Reference<\/p>\n
Carpentieri A, Mascia P, Fornaro M, et al. Effectiveness and safety of secukinumab in patients with moderate-severe psoriasis: A multicenter real-life study. [published online July 18, 2020]. Dermatol Ther. doi:10.1111\/dth.14044<\/p>\n
<\/p>\n
Follow this link:<\/p>\n
Secukinumab Effective in Real-Life Patients With Moderate-Severe Psoriasis - Dermatology Advisor<\/a><\/p>\n","protected":false},"excerpt":{"rendered":" Secukinumab may be a safe and effective treatment for patients with psoriatic disease, comorbidities, and treatment failure, according to results of a retrospective study published in Dermatologic Therapy. The fully human IgG1\/k monoclonal antibody has been shown to be safe and effective in the treatment of psoriasis in phase 3 trials, but has not yet been tested in the general population. To determine the clinical effectiveness and safety of secukinumab in a real-life cohort of patients with moderate to severe psoriasis vulgaris, data from 120 patients (35.8% women) were analyzed Continue reading